Singapore, June 13 -- Singapore-based biopharmaceutical companySpecialised Therapeutics (ST) has expandedits existing supply and distribution agreement with Incyte Biosciences International Sarl, the Swiss-based affiliate of Incyte, to launch and distribute two additional medicines from its oncology portfolio in Australia, New Zealand and Singapore, with an option to add further countries in the Asia-Pacific(APAC) region.

The expanded agreement will see new therapies axatilimab (registered as Niktimvoin the United States) and retifanlimab (registered as Zynyzin the US and European Union) added to the current partnered portfolio of Minjuvi(tafasitamab) and Pemazyre(pemigatinib).

ST anticipates submitting axatilimab and retifanlimab for l...